BRAF Codon 600 Missense Cancer Clinical Trials

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

221 sites for NCT04511013

BRAF Codon 600 Missense

Melanoma

binimetinib, +3 more drugs

immunotherapy, +1 more type

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

10 sites for NCT03297606

ABL1 Fusion, +98 more biomarkers

B-Cell Non-Hodgkin Lymphoma, +2 more conditions

axitinib, +15 more drugs

immunotherapy, +1 more type

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

39 sites for NCT04417621

BRAF Codon 600 Missense, +1 more biomarker

Cutaneous Melanoma

LTT462, +3 more drugs

targeted therapy

A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations

20 sites for NCT04302025

ALK Fusion, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +8 more drugs

chemotherapy, +4 more types

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

18 sites for NCT04294160

BRAF Codon 600 Missense

Colorectal Carcinoma

dabrafenib, +5 more drugs

immunotherapy, +1 more type

A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors

5 sites for NCT04913285

BRAF Codon 600 Missense, +28 more biomarkers

Malignant Solid Tumor, +1 more condition

binimetinib, +1 more drug

targeted therapy

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

1 site for NCT04741997

BRAF Codon 600 Missense

Melanoma

binimetinib, +3 more drugs

immunotherapy, +2 more types

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

7 sites for NCT04544111

BRAF Codon 600 Missense

Poorly Differentiated Thyroid Gland Carcinoma, +2 more conditions

dabrafenib, +2 more drugs

immunotherapy, +1 more type

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

1 site for NCT02910700

BRAF Codon 600 Missense

Melanoma

binimetinib, +4 more drugs

immunotherapy, +1 more type

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

5 sites for NCT04249843

ARAF Mutation, +44 more biomarkers

Cutaneous Melanoma, +3 more conditions

BGB3245

targeted therapy

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations